Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06155539 | NOT YET RECRUITING | Diabetes Mellitus, Type 2

A Study of Blood Metabolic Markers in Patients With Type 2 Diabetes Mellitus of Different Stages
Sponsor:

Peng Wu

Information provided by (Responsible Party):

Peng Wu

Brief Summary:

Metabolomics is an emerging "omics" after genomics, transcriptomics and proteomics, which can reflect the physiological state of organisms more directly and accurately. Whether metabolite differences exist in patients with type 2 diabetes of different stages and whether such metabolite differences can be used as potential markers have not yet been studied, which is of great significance to explore. In this study, 105 patients with different stages of type 2 diabetes mellitus were enrolled according to the inclusion and exclusion criteria, and the metabolites in the samples were detected by ultra-high performance liquid chromatography coupled with tandem time-of-flight mass spectrometry (UHPLC-Q-TOF MS) after the blood samples were collected, and the corresponding investigative data were collected, and then baseline and demographic analyses, metabolomics data processing, and analysis of the results were carried out to provide a reference for the identification of metabolic markers and to provide a reference for the identification of significant metabolic markers in diabetic patients.

Condition or disease

Diabetes Mellitus, Type 2

Intervention/treatment

No intervention

Study Type : OBSERVATIONAL
Estimated Enrollment : 105 participants
Official Title : A Study of Blood Metabolic Markers in Patients With Type 2 Diabetes Mellitus of Different Stages
Actual Study Start Date : 2024-01-01
Estimated Primary Completion Date : 2025-05-31
Estimated Study Completion Date : 2025-12-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 75 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Age 18 to 75 years old
  • 2. Population of patients with type 2 diabetes mellitus of different stages
  • 3. Subjects or legal representatives gave informed consent to voluntarily join the study by signing an informed consent form.
Exclusion Criteria
  • 1. patients with severe acute underlying brain, cardiac, pulmonary, hepatic, renal and other conditions that the investigator believes to be influential
  • 2. Patients diagnosed with any malignancy within the previous 5 years;
  • 3. Received any form of oncological treatment including surgery, radiotherapy/chemotherapy, endocrine therapy, targeted therapy and immunotherapy prior to entry for blood sampling;
  • 4. Organ transplant recipients or previous non-autologous (allogeneic) bone marrow or stem cell transplant recipients;
  • 5. Those who have received blood transfusion therapy 1 month prior to the blood draw;
  • 6. Patients with blood-borne diseases such as hepatitis, syphilis, and HIV;
  • 7. Patients with other factors that, in the opinion of the investigator, influence the study.
A Study of Blood Metabolic Markers in Patients With Type 2 Diabetes Mellitus of Different Stages

Location Details

NCT06155539

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

China, Shandong

Peng Wu

Women, Shandong, China, 250014